Clinicians are best placed to determine who needs it
In a quiet but consequential shift, New Zealand has chosen to place trust in its clinicians over bureaucratic checklists, opening access to a widely used cholesterol-lowering medication to tens of thousands more people from October 2026. Pharmac's decision to remove all eligibility criteria for Rosuvastatin — including restrictions tied to ethnicity — reflects a broader reckoning with how administrative barriers can delay care that is both medically sound and fiscally responsible. The change asks a simple question that health systems everywhere must eventually answer: if a doctor believes a patient needs a medicine, what purpose does a gatekeeping form truly serve?
- Around 76,000 New Zealanders currently use Rosuvastatin, but eligibility rules — some tied to ethnicity — have kept tens of thousands of at-risk patients from accessing it.
- From October 1, 2026, all restrictions disappear, shifting the prescribing decision entirely to clinicians and their assessment of cardiovascular risk.
- Pharmac projects 81,000 additional people will gain access in the first year, growing to 108,000 over five years — a near-doubling of the medication's reach.
- The expansion carries no new funding requirement, absorbed instead through Pharmac's existing tender budget, which routinely frees up $30–50 million annually through price negotiations.
- Pharmac bypassed further public consultation, judging that prior engagement had already established clear support and that delay would cost lives that earlier access could protect.
From October 1, 2026, New Zealand will remove all eligibility restrictions on Rosuvastatin, a cholesterol-lowering medication that reduces the risk of heart attacks and strokes. Where bureaucratic criteria — including rules based on ethnicity — once determined who could access the drug, clinical judgment will now be the only threshold that matters.
The shift has the support of Associate Health Minister David Seymour, who frames it as part of a wider effort to reduce friction in medicine access. The reasoning is direct: doctors understand their patients' cardiovascular risk better than any checklist, and removing administrative barriers means earlier intervention for people who need it most.
The scale of the change is significant. Pharmac estimates that approximately 81,000 additional New Zealanders will access Rosuvastatin in the first year, with that figure growing to around 108,000 over five years — nearly doubling the current user base of 76,000. The medication remains prescription-only; the gatekeeper simply changes from a form to a physician.
No new funding is required. Pharmac will absorb the cost through its existing annual tender budget, which typically generates $30–50 million in savings through pharmaceutical price negotiations — money that can be redirected toward expanded treatments like this one.
Phamac chose not to run additional public consultation, concluding that previous rounds of engagement had already demonstrated strong support. Moving quickly, the agency reasoned, was itself a form of care — the sooner access opens, the sooner the medication can prevent the heart attacks and strokes it was designed to forestall.
For those already receiving Rosuvastatin, nothing changes. The expansion is purely additive, opening a door for patients who previously fell outside the criteria but whose doctors now judge them to be good candidates. It is, in the end, a calculated wager that trusting clinicians over paperwork will yield better health outcomes without straining the budget.
Starting October 1st, New Zealand's pharmaceutical funding agency will remove all restrictions on who can access Rosuvastatin, a cholesterol-lowering medication that reduces the risk of heart attacks and strokes. The decision marks a significant shift in how the drug is distributed—instead of eligibility criteria determining access, including rules based on ethnicity, clinicians will now decide which patients need it based on clinical judgment alone.
The change has the backing of Associate Health Minister David Seymour, who frames it as part of the government's broader effort to improve medicine access. The logic is straightforward: doctors are best positioned to know their patients' cardiovascular risk and whether Rosuvastatin would help them. Removing bureaucratic barriers means faster prescribing decisions and earlier intervention for people at risk of serious cardiac events.
The numbers suggest the impact will be substantial. Currently, around 76,000 New Zealanders use Rosuvastatin each year. Pharmac estimates that once the eligibility criteria disappear, approximately 81,000 additional people will access the drug in the first year alone. Over five years, that figure is projected to grow to about 108,000 more people. The medication will remain prescription-only, so it won't become available over the counter—the gatekeeper simply shifts from a bureaucratic checklist to the doctor's clinical assessment.
Funding the expansion doesn't require new money. Pharmac will absorb the cost through its existing annual tender budget, the mechanism it uses to manage overall pharmaceutical spending by negotiating lower prices on medicines already in the system. The agency typically frees up between $30 million and $50 million annually through this process, money that can be redirected toward new or expanded treatments. In this case, widening Rosuvastatin access fits within that existing financial envelope.
Seymour emphasizes the downstream benefits: better management of high cholesterol across the population should prevent avoidable hospital admissions and reduce pressure on other parts of the health system. When people can access preventive medications more easily, they tend to stay healthier longer, which means fewer emergency interventions and fewer beds occupied by patients with preventable cardiovascular events.
Pharmac chose not to conduct additional public consultation before making this decision, reasoning that previous consultations, funding decisions, and engagement with health professionals and consumers had already demonstrated strong support. Rather than delay implementation with another round of feedback, the agency decided to move forward quickly. The sooner people can get the medication, the thinking goes, the sooner it can do its work.
People already receiving Rosuvastatin will see no change to their prescriptions or access. The expansion is purely additive—it opens the door to those who previously fell outside the eligibility criteria but whose doctors now believe they would benefit from the drug. For a health system constantly balancing cost against need, the decision represents a calculated bet that removing friction from the prescribing process will yield better health outcomes without breaking the budget.
Notable Quotes
Clinicians are best placed to determine who needs Rosuvastatin. If a clinician thinks a patient would benefit from this medicine, they should be able to prescribe it to them, regardless of their ethnicity.— Associate Health Minister David Seymour
Supporting earlier and more effective management of high cholesterol for everyone will reduce avoidable hospital admissions and improve health outcomes.— Associate Health Minister David Seymour
The Hearth Conversation Another angle on the story
Why remove ethnicity from the criteria specifically? That seems like it was doing something deliberate before.
It was. The previous rules restricted access based on ethnicity, which meant some people couldn't get the drug even if their doctor thought they needed it. Removing that barrier means clinical need becomes the only gate.
So this is about equity—making sure ethnicity doesn't determine who gets preventive care.
Partly, yes. But it's also practical. If a clinician thinks someone's at risk of a heart attack, why should ethnicity matter? The drug works the same way in everyone's body.
And Pharmac can actually afford this without cutting something else?
They're using their annual tender savings—the money they free up by negotiating better prices on existing drugs. It's built into their normal budget cycle, not a new expense.
What happens if 81,000 more people start taking it and the costs balloon?
That's the risk. But Pharmac's betting that preventing heart attacks and strokes is cheaper than treating them in hospitals. And they've already factored in the projected numbers.
Why skip the consultation process?
They'd already heard from doctors and patients that people wanted this. Doing another round felt like delay for delay's sake. The sooner people can access it, the sooner it prevents harm.